Photobiomodulation in the management of oral disease: dose, mechanisms and practical considerations
Frontiers in Oral Health · 16.11.2026 · 7
DOI: 10.3389/froh.2026.2015491 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oral Health, online erschienen am 16.11.2026. Verfasst von Gal Hiltch und 3 weiteren Autor:innen. Die Arbeit nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Photobiomodulation (PBM) uses non-ionizing light, mainly red and near-infrared, at non-thermal doses to modulate inflammation and promote tissue repair. This review assesses the evidence for PBM in oral disease using an evidence hierarchy. Prevention of oral mucositis (OM), its strongest indication, has reached guideline-level recommendation and should be available for patients receiving head and neck radiotherapy with or without chemotherapy, or high-dose chemotherapy with stem cell transplantation. For pain after third molar surgery and endodontic treatment, meta-analyses show only short-term benefits with low certainty of evidence. The BMJ clinical guideline regarding pain management of temporomandibular disorders (TMD) issued a conditional recommendation against PBM. Similarly, the European Federation of Periodontology (EFP) and the American Dental Association (ADA) have not found clinical benefits and both guidelines recommend against adjunctive laser therapy. In orthodontics, Cochrane reviews found low to very low certainty evidence for either pain reduction or shortening of treatment time. Evidence for implant osseointegration, nerve recovery, burning mouth syndrome, and other mucosal conditions remains limited to small trials. Methodology varied across indications: missing dosimetry information prevents replication of trials, and lack of verified patient blinding is a concern. With eyewear protection, PBM's safety profile is high; its use over oncological areas, however, still lacks clinical evidence. For other indications, evidence does not support routine use, and PBM should be used with patient consent and explanation of unproven benefit. Complete documentation of treatment parameters is recommended, and regulatory clearance of a device should not be interpreted as evidence of clinical efficacy.
Zitieren
APA
Hiltch, G., Steier, L., Figueiredo, J. A. P. D., & Martins, M. (2026). Photobiomodulation in the management of oral disease: dose, mechanisms and practical considerations. Frontiers in Oral Health, 7. https://doi.org/10.3389/froh.2026.2015491
Vancouver
Hiltch G, Steier L, Figueiredo JAPD, Martins M. Photobiomodulation in the management of oral disease: dose, mechanisms and practical considerations. Frontiers in Oral Health. 2026;7. doi:10.3389/froh.2026.2015491
BibTeX
@article{Hiltch2026,
author = {Hiltch, Gal and Steier, Liviu and Figueiredo, José Antonio Poli De and Martins, Manoela},
title = {Photobiomodulation in the management of oral disease: dose, mechanisms and practical considerations},
journal = {Frontiers in Oral Health},
year = {2026},
volume = {7},
doi = {10.3389/froh.2026.2015491}
}
EUVIMED